Background
==========

Medulloblastoma was first described by Harvey Cushing and Percival Bailey in 1925 and is a malignant tumor that develops in neuroepithelial tissue in the central nervous system. It is also the most common malignant primary brain tumor that develops in children \[[@b1-medscimonit-23-4454],[@b2-medscimonit-23-4454]\]. Despite the development of multiple therapeutic strategies in recent years, including surgical resection, adjuvant chemotherapy, and cranio-spinal irradiation, the prognosis of medulloblastoma remains unsatisfactory. Moreover, the survival rates for patients with medulloblastoma have been found to decrease with patient age, and children have higher rates of survival than adults \[[@b3-medscimonit-23-4454]\]. Over the past few decades, many genes that mediate the development and prognosis of medulloblastoma have been discovered \[[@b3-medscimonit-23-4454],[@b4-medscimonit-23-4454]\]. These efforts have revealed four distinct subgroups (WNT, SHH, Group 3, Group 4) rather than one single morphological entity. Each subgroup has a characteristic survival rate, age demographics, and genetic aberrations \[[@b5-medscimonit-23-4454]\]. For example, 90% of WNT patients have somatic missense mutations in CTNNB1 \[[@b6-medscimonit-23-4454]\], while amplification of *GLI2* and *MYCN*, as well as missense mutations in *MSO*, *PTCH*, and *SUFU*, are generally observed in SHH patients \[[@b7-medscimonit-23-4454]--[@b10-medscimonit-23-4454]\]. In contrast, genome alterations associated with Group 3 are diverse and are often shared with Group 4.

Long non-coding RNAs (lncRNAs) are a group of transcribed RNA molecules with lengths exceeding 200 nucleotides \[[@b11-medscimonit-23-4454],[@b12-medscimonit-23-4454]\] that do not encode proteins, yet they contribute to the expression and regulation of various genes \[[@b13-medscimonit-23-4454]\]. Over the past few years, lncRNAs have been found to have roles in the tumorigenesis, metastasis, and prognosis of various cancers \[[@b14-medscimonit-23-4454]\]. Human UCA1 is an lncRNA that is composed of three exons that encode a 1.4 kb isoform and a 2.2 kb isoform \[[@b15-medscimonit-23-4454]\]. UCA1 was first detected in human bladder carcinoma \[[@b16-medscimonit-23-4454]\] and has since been found to contribute to several epithelial cancers, including bladder, prostate, breast, non-small cell lung, tongue squamous cell, esophageal squamous cell, gastric, colorectal, hepatocellular, melanoma, and ovarian cancers \[[@b17-medscimonit-23-4454]--[@b27-medscimonit-23-4454]\]. However, the role of UCA1 in medulloblastoma remains to be elucidated. Therefore, in the present study, expression levels of UCA1 in medulloblastoma specimens and cell lines were initially detected with quantitative real-time PCR. We next investigated whether abnormal expression of UCA1 affects the proliferation, migration, apoptosis, and cell cycle progression of medulloblastoma cells.

Material and Methods
====================

Patient samples
---------------

Ten medulloblastoma specimens and corresponding nontumor adjacent tissue specimens were obtained from the Department of Neurosurgery, Zhujiang Hospital of Southern Medical University, China, between 2014 and 2016. Each specimen was preserved in liquid nitrogen before being prepared for pathological analysis in the Department of Pathology, Zhujiang Hospital of Southern Medical University, China. Informed consent was obtained after patients were made aware of the aims and sample collection process for this study. This study was approved by the ethics committee of Zhujiang Hospital of Southern Medical University according to the Declaration of Helsinki.

Cell culture
------------

The human medulloblastoma cell line, Daoy, and the human glioma cell line, U251, were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Both cell lines were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The human medulloblastoma cell line, D283, was obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in RPMI 1640 supplemented with 15% FBS and 1% penicillin/streptomycin. All of the cells were maintained in a humidified atmosphere containing 5% CO~2~ at 37°C.

Quantitative real-time PCR
--------------------------

A homogenate of each medulloblastoma specimen was obtained according to a liquid nitrogen grounding method. Total RNA was then extracted from each homogenate with the RNAiso Plus kit (Takara Bio Inc.) according to the manufacturer's instructions. Reverse transcription was performed with the PrimeScript™ RT reagent kit (Takara Bio Inc.) and Veriti 96-Well Thermal Cycler (Applied Biosystems, Foster City, CA, USA) to obtain cDNA. Quantitative PCR was performed with the ECO™ Real-time PCR System (Illumina, San Diego, CA, USA) and SYBR^®^ Premix Ex Taq™ II (Takara Bio Inc.). Detection of GAPDH and 18S were performed as internal controls. Forward and reverse primers for the following targets were used (Sangon Biotech Co.): human UCA1: 5′-TGTTAGAGGGCTTGGGACAT-3′ and 5′-ATAGGTGTGAGTGGCGGTCT-3′; human GAPDH: 5′-CAGGA GGCATTGCTGATGAT-3′ and 5′-GAAGGCTGGGGCTCATTT-3′; human 18S: 5′-GTAACCCGTTGAACCCCATT-3′ and 5′-CCATCCA ATCGGTAGTAGCG-3′, respectively in each case.

Short hairpin RNA (shRNA) constructs and viral infection
--------------------------------------------------------

A shRNA targeting *UCA1* and a negative control shRNA were designed and synthesized (GenePharma, Shanghai, China). These shRNAs were subsequently inserted into a lentivirus vector (GenePharma, Shanghai, China) and transfected into medulloblastoma cells. Stable expression clones were selected by puromycin according to the manufacturer's instructions and knockdown efficiency was determined with quantitative real-time PCR assays.

Cell proliferation assay
------------------------

Cell proliferation was detected with a cell counting kit (CCK)-8 (Dojindo, Japan) as described in previous articles \[[@b28-medscimonit-23-4454]\]. Briefly, cells were added to a 96-well plate (2,000 cell/well) and incubated for various periods of time (0, 24, 48, and 72 hours) in a humidified atmosphere containing 5% CO~2~ at 37°C. Then, 10 μL of CCK-8 solution was added to each well. The plates were incubated for an additional 2 hours until absorbance values at 450 nm were recorded with a microplate reader.

Flow cytometry analysis
-----------------------

Medulloblastoma cells were cultured in 6-well plates for a suitable period that cells were grown to reach 70--80% confluence. The cells were then rinsed 3 times with PBS and fixed in 70% ethanol for 2 hours at 4 °C. Each sample was resuspended in 100 uL of PBS containing RNase A (2 mg/mL; Sigma Aldrich, St. Louis, USA) and propidium iodide (100 mg/mL; Sigma Aldrich). Fluorescence activated cell sorting (FACS) analysis was performed to detect the distribution of cells among the various phases of the cell cycle.

Scratch wound healing assay
---------------------------

Cell migration was investigated in scratch wound healing assays. Briefly, cells were cultured in 6-well plates until they reached 90% confluency. Scratch wounds were then made in the bottom of each well with a pipette tip. The medium from each well was subsequently removed and replaced with serum-free culture media. At various time points, the wounds were observed and imaged with an inverted microscope. Then divide the original scratch wound width by average wound width after culture, we get the results of%wound closure.

Transwell migration assay
-------------------------

Cell migration assays were performed with Transwell inserts with 8-μm pore size polycarbonate membranes (Corning, Corning, NY, USA). Briefly, cells in serum-free culture media were added into the upper chambers of each Transwell insert. The lower chamber for each well contained media supplemented with 20% FBS. After 24 hours in a humidified atmosphere of 5% CO~2~ at 37°C, the cells on the upper membrane surface were removed mechanically with cotton swabs \[[@b29-medscimonit-23-4454]\]. The filters were then fixed with methanol for 20 minutes and stained with a 0.1% crystal violet solution for 15 minutes. The number of migrating cells observed in five random fields with an inverted microscope was recorded and representative images were acquired with Image-Pro Plus 6.

Statistical analysis
--------------------

Data are presented as the mean ± standard deviation (SD). All statistical analyses included Student's *t*-tests were analyzed using SPSS 19.0 Windows version software (SPSS, Chicago, IL, USA). A *p* value less than 0.05 was considered statistically significant.

Results
=======

Expression of *UCA1* in medulloblastoma specimens and cell lines
----------------------------------------------------------------

We initially compared the expression levels of *UCA1* between 10 pairs of medulloblastoma tissues and corresponding adjacent nontumor normal tissues with RT-PCR. The levels of *UCA1* in the medulloblastoma specimens were approximately 30% higher than the levels detected in the nontumor adjacent tissues (*p*\<0.05; [Figure 1](#f1-medscimonit-23-4454){ref-type="fig"}). The levels of *UCA1* expression were also compared with the characteristics of the patients from whom the specimens were resected ([Table 1](#t1-medscimonit-23-4454){ref-type="table"}). Among these patients, 8/10 were younger than 10 years of age and 3/10 were female. The resected tumors were located in the fourth ventricle for 5/10 of the patients, and the rest of the tumors were located in the cerebellum. Eight of the patients developed distant metastasis and all 10 patients were diagnosed with stage IV medulloblastoma according to the World Health Organization criteria.

The mRNA levels of *UCA1* were also detected in the medulloblastoma cell lines, Daoy and D283, and in the glioma cell line, U251, with quantitative PCR. *UCA1* expression was markedly higher in the Daoy cell line compared to the D283 and U251 cell lines (*p*\<0.05; [Figure 1C](#f1-medscimonit-23-4454){ref-type="fig"}).

Knockdown of *UCA1* in medulloblastoma cells by lentiviral shRNA
----------------------------------------------------------------

To elucidate the importance of *UCA1* in medulloblastoma, stable knockdown expression clones were established in Daoy cells. Briefly, a shRNA designed to target *UCA1* was constructed, packaged in a lentivirus vector, and transfected into Daoy cells (referred to as the shUCA1 group). A negative control lentiviral shRNA was generated and transfected in parallel (referred to as the NC group). Quantitative RT-PCR detected a knockdown efficiency of 60% for these shRNAs (*p*\<0.05; [Figure 2A](#f2-medscimonit-23-4454){ref-type="fig"}).

Knockdown of *UCA1* alters cell proliferation, cell cycle, and migration of medulloblastoma cells *in vitro*
------------------------------------------------------------------------------------------------------------

To detect possible biological roles of *UCA1* in the tumorigenicity of medulloblastoma, the proliferation, cell cycle progression, and migration of Daoy cells following knockdown of *UCA1* were assayed. In the CCK-8 assays that were performed to detect cell proliferation, the OD450 values for the shUCA1 group were 30% lower compared with the NC group (*p*\<0.05; [Figure 2B](#f2-medscimonit-23-4454){ref-type="fig"}). In the analysis of cell cycle progression with flow cytometry, silencing of *UCA1* in the Daoy cells induced a cell cycle arrest in the G0/G1 phase compared to the NC group. In addition, the number of cells in the S phase significantly decreased ([Figure 2C, 2D](#f2-medscimonit-23-4454){ref-type="fig"}).

To examine the influence of *UCA1* silencing on the migration ability of Daoy cells, scratch wound healing and Transwell migration assays were performed. In the former assays, the cell free area was significantly wider in the shUCA1 group than in the NC group ([Figure 3A](#f3-medscimonit-23-4454){ref-type="fig"}), with a 56.16% reduction in migration observed for the shUCA1 group versus the NC group (*p*\<0.05; [Figure 3B](#f3-medscimonit-23-4454){ref-type="fig"}). Similarly, the results of the Transwell migration assays showed that knockdown of *UCA1* significantly suppressed migration by 44.64% compared to the NC group (*p*\<0.05; [Figure 3C 3D](#f3-medscimonit-23-4454){ref-type="fig"}).

Discussion
==========

Medulloblastoma is the most common malignant intracranial tumor during childhood, and it currently accounts for approximately 20% of the tumors of the central nervous system in children \[[@b30-medscimonit-23-4454]\]. With the development of multiple therapeutic strategies, the survival rate of medulloblastoma has improved \[[@b31-medscimonit-23-4454]\]. However, the quality of life for medulloblastoma survivors is frequently affected by neurocognitive sequelae. Thus, safer and more efficient targeting therapies are needed. Among the long non-coding RNAs that have been identified as having roles in a wide range of biological processes in tumors \[[@b14-medscimonit-23-4454]\], UCA1 is of particular interest to our laboratory. Based on the diverse oncogenic functions that UCA1 has been associated with in a variety of epithelial cancers, it appears that UCA1 affects the proliferation, migration, invasion, apoptosis, and cell cycle progression of these cancers \[[@b15-medscimonit-23-4454]--[@b27-medscimonit-23-4454]\]. In addition, UCA1 has been shown to contribute to the WNT, SUFU, and PI3K/AKT pathways as well \[[@b32-medscimonit-23-4454]\]. Therefore, the oncogenic effect of UCA1 in medulloblastoma was investigated here.

In the present study, expression of *UCA1* was detected by RT-PCR and was found to be expressed at markedly higher levels in all ten medulloblastoma samples that were examined compared with the corresponding paired nontumor adjacent tissues. Moreover, for the medulloblastoma cell lines (Daoy and D283) and glioma cell line (U251) that were assayed by the same method, the *UCA1* levels detected in the Daoy cell line were significantly higher than the levels detected in the D283 and U251 cell lines. Thus, Daoy cells were confirmed to be a suitable cell line for the knockdown of *UCA1* expression via lentiviral shRNA and the selection of stable expression clones. As a result, proliferation of the Daoy cells with silenced *UCA1* was found to be reduced due to cell cycle arrest in the G0/G1 phase, and this was accompanied by a marked decrease in the number of cells in the S phase. However, this cell cycle arrest was not accompanied by a significant increase in apoptosis. Furthermore, *UCA1* silencing markedly suppressed the migration ability of the Daoy cells compared to the negative control group.

To date, four distinct subgroups of medulloblastoma have been identified, including WNT, SHH, Group 3, and Group 4, and each subgroup has its own genetic features. In the WNT subgroup, the WNT signaling pathway is activated. The WNT pathway has been shown to play an important role in cell fate specification, cell proliferation, and cell migration \[[@b33-medscimonit-23-4454]\]. In bladder cancer, Fan et al. showed that UCA1 is able to activate the WNT signaling pathway and also upregulate Wnt6 expression \[[@b33-medscimonit-23-4454]\]. Recent research has also demonstrated that UCA1 can activate the PI3K/AKT signaling pathway in bladder cancer \[[@b34-medscimonit-23-4454]\]. In the SHH subgroup, the SHH signaling pathway is excessively activated and GLI is overexpressed \[[@b33-medscimonit-23-4454]\]. In combination, these events facilitate tumor formation. Li et al. further discovered that mTOR is upregulated by UCA1 \[[@b35-medscimonit-23-4454]\]. Thus, activation of PI3K/AKT and mTOR by UCA1 has the potential to inhibit SUFU, a negative regulatory factor of GLI, thereby promoting activation of the SHH signaling pathway \[[@b32-medscimonit-23-4454]\]. Meanwhile, SUFU can bind to β-catenin to inhibit binding interactions between β-catenin and Tcf/Lef, thereby inactivating the WNT signaling pathway \[[@b36-medscimonit-23-4454]\]. All of these interactions represent potential mechanisms by which UCA1 may contribute to the proliferation, migration, and cell cycle progression of the Daoy medulloblastoma cell line, and possibly to medulloblastomas *in vivo* as well.

There were limitations associated with the present study. First, there were no significant differences observed regarding the possible correlations between UCA1 expression and the clinical features and prognosis of the patients examined. We hypothesize that this is due to the limited number of samples that were examined. Second, although an oncogenic function was demonstrated for UCA1 in medulloblastoma in the present study, the mechanisms and downstream mediators that mediate this function remain to be identified.

Conclusions
===========

To the best of our knowledge, the results of the present study show for the first time that UCA1 is overexpressed in medulloblastomas both *in vivo* and *in vitro*. Furthermore, silencing of *UCA1* resulted in a significant inhibition of cell proliferation and migration *in vitro* and induced a G0/G1 phase arrest. Thus, targeting of *UCA1* appears to represent a potentially effective approach for treating medulloblastoma and further study is warranted.
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![Levels of *UCA1* mRNA detected in the medulloblastoma samples and cell lines examined (t-test). (**A**) Relative mRNA levels of *UCA1* that were detected in ten medulloblastoma specimens and paired nontumor adjacent tissues. (**B**) The mean levels of *UCA1* from the data in (**A**) (*p*\<0.05). (**C**) Relative *UCA1* expression levels in the medulloblastoma cell lines, Daoy and D283, compared with the glioma cell line, U251 (*p*\<0.05). All data are presented ±SD.](medscimonit-23-4454-g001){#f1-medscimonit-23-4454}

![Results of the CCK-8 assays and flow cytometry analyses performed following the knockdown of *UCA1* in the Daoy cells (t-test). (**A**) Relative expression levels of *UCA1* ±SD in the shUCA1 and NC groups as detected by RT-PCR (*p*\<0.05). (**B**) OD450 values ±SD for the shUCA1 group were reduced by 30% compared to the NC group in the CCK-8 assays (*p*\<0.05). (**C**) The distribution of cells among the phases of the cell cycle for the shUCA1 and NC groups as detected by flow cytometry. (**D**) The percentage of cells that were distributed among the three phases of the cell cycle ±SD in the shUCA1 and NC groups.](medscimonit-23-4454-g002){#f2-medscimonit-23-4454}

![Results of the wound scratch healing and Transwell migration assays (t-test). (**A**) Representative images of wound scratch healing assays for the shUCA1 group and the NC group 0 hour and 48 hours after the start of the assay (*p*\<0.05). (**B**) Quantitation of the amount of wound closure measured for the shUCA1 and NC groups ±SD. (**C**) Representative images of the Transwell migration assay data for the shUCA1 and NC groups 24 hours after the start of the assay. (**D**) Number of migrating Daoy cells that were counted for shUCA1 group and NC group ±SD (*p*\<0.05).](medscimonit-23-4454-g003){#f3-medscimonit-23-4454}

###### 

*UCA1* Expression and the characteristics of the patients from whom the medulloblastoma specimens and nontumor specimens were resected (n=10).

  Patient no.   Gender   Age (y)   Tumor length (cm)   Tumor location    Distant metastasis   p53 expression   UCA1 expression
  ------------- -------- --------- ------------------- ----------------- -------------------- ---------------- -----------------
  1             Male     7         4.6                 4^th^ ventricle   −                    \+               −
  2             Male     37        5.5                 Cerebellum        −                    \+               −
  3             Female   2         6.3                 Cerebellum        −                    \+               −
  4             Male     7         4.1                 Cerebellum        −                    −                −
  5             Male     6         4.9                 4^th^ ventricle   −                    −                \+
  6             Male     5         4.5                 Cerebellum        −                    \+               −
  7             Female   2         5.7                 4^th^ ventricle   −                    \+               \+
  8             Male     6         3.8                 4^th^ ventricle   −                    \+               −
  9             Male     8         3.6                 4^th^ ventricle   \+                   −                \+
  10            Female   34        4.0                 Cerebellum        \+                   \+               −

'+' -- positive; '−' -- negative. Positive UCA1 expression was defined as a level of UCA1 expression in the medulloblastoma.
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